Stockscreener 앱 받기
36.17
1.52%
-0.56
시간 외 거래:
36.58
0.41
+1.13%
전일 마감가:
$36.73
열려 있는:
$37
하루 거래량:
2.68M
Relative Volume:
1.02
시가총액:
$4.86B
수익:
-
순이익/손실:
$-237.54M
주가수익비율:
-14.45
EPS:
-2.5033
순현금흐름:
$-145.05M
1주 성능:
-6.80%
1개월 성능:
-19.28%
6개월 성능:
+95.83%
1년 성능:
+0.00%
1일 변동 폭
$36.14
$37.00
1주일 범위
$35.89
$40.39
52주 변동 폭
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
명칭
Definium Therapeutics Inc
전화
212-220-6633
주소
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, MRNA, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
36.17 | 4.86B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-17 | 개시 | Stifel | Buy |
| 2026-04-10 | 개시 | Piper Sandler | Overweight |
| 2026-02-24 | 개시 | Wolfe Research | Outperform |
| 2026-01-30 | 개시 | Jefferies | Buy |
| 2025-10-13 | 개시 | Needham | Buy |
| 2025-08-04 | 재개 | Oppenheimer | Outperform |
| 2025-01-28 | 개시 | Evercore ISI | Outperform |
| 2024-12-20 | 개시 | Chardan Capital Markets | Buy |
| 2024-10-14 | 재개 | Leerink Partners | Outperform |
| 2024-07-24 | 개시 | ROTH MKM | Buy |
| 2024-05-29 | 개시 | Robert W. Baird | Outperform |
| 2024-04-15 | 개시 | Leerink Partners | Outperform |
| 2023-12-05 | 개시 | Canaccord Genuity | Buy |
| 2022-12-09 | 재개 | ROTH Capital | Buy |
| 2022-11-16 | 개시 | RBC Capital Mkts | Outperform |
| 2022-08-26 | 개시 | Oppenheimer | Outperform |
| 2022-08-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-04 | 개시 | ROTH Capital | Buy |
| 2021-06-28 | 개시 | Maxim Group | Buy |
모두보기
Definium Therapeutics Inc 주식(DFTX)의 최신 뉴스
Form 144 DEFINIUM THERAPEUTICS For: 26 September - Investing.com India
Form 144 DEFINIUM THERAPEUTICS For: 25 September By Investing.com - Investing.com Nigeria
An officer sold 2,867 shares in the prior three months and lists 3,097 for sale at Definium Therapeutics (DFTX). - Stock Titan
After selling 13,008 shares in June, Definium Therapeutics (DFTX) officer Mark Sullivan proposes to sell 14,051. - Stock Titan
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression - Yahoo Finance
Definium Therapeutics, Inc. (DFTX) Options ChainYahoo Finance - Yahoo! Finance Canada
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
Definium Therapeutics at TD Cowen summit: phase iii data lift dt120 - Investing.com
Definium Therapeutics reports 5.1‑point gap in second Phase 3 anxiety study - Mugglehead Investment Magazine
Definium Therapeutics, Inc. (DFTX) Latest Stock News & Headlines - Yahoo Finance
A Quick Look at Today's Ratings for Definium Therapeutics(DFTX.US), With a Forecast Between $66 to $91 - Moomoo
Definium Therapeutics, Inc. (DFTX) latest stock news and headlines - Yahoo Finance Singapore
Definium Therapeutics, Inc. (NASDAQ: DFTX) Stock Price, News & Analysis - kalkine.ca
Definium’s LSD Pill Clears a Second Anxiety Trial, and the Psychedelics Sector Is Watching - finance.yahoo.com
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX) - The Globe and Mail
Definium Therapeutics’ DT120 Hits Phase III Goals in Anxiety Study - finance.yahoo.com
Director at Definium Therapeutics (DFTX) now holds 22,296 shares - Stock Titan
Director boosts Definium (DFTX) stake with option exercise - Stock Titan
Definium Reports Second Phase III Success in Anxiety Disorder Program - The Globe and Mail
Definium Therapeutics (DFTX) Stock May Trade At A Premium Despite Phase 3 DT120 Results - Yahoo Finance
Why Definium Therapeutics (DFTX) Is Up 5.7% After Second Positive Phase 3 DT120 Anxiety Trial Result - Yahoo Finance
Definium Therapeutics (DFTX) After Its Phase 3 Win Still Looks Undervalued - Yahoo Finance
Definium Therapeutics Jumps 20% After Third Phase 3 Win for LSD-Based Anxiety Drug - finance.biggo.com
Stifel raises Definium Therapeutics stock price target on trial win By Investing.com - Investing.com Nigeria
Definium Therapeutics Rises as Investors Weigh Recent Regulatory Momentum and Near-Term Data Catalysts - quiverquant.com
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy' - Benzinga
Definium (DFTX) CEO awarded 750,000 shares tied to clinical milestones - Stock Titan
Definium Therapeutics (DFTX) awards 125K performance shares tied to 2028 milestones - Stock Titan
Definium Therapeutics reports positive Phase 3 Panorama topline: DT120 ODT 100 µg shows -5.1 HAM-A benefit - TradingView
Definium Therapeutics (DFTX) posts third positive Phase 3 anxiety result ahead of planned NDA submission - Stock Titan
Definium Therapeutics stock jumps on positive trial results By Investing.com - Investing.com Nigeria
Definium Therapeutics stock jumps on positive trial results - Investing.com
S&P 500 Futures Decline in Premarket Trading; Definium Therapeutics, Primo Brands Lead - Barron's
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder - Business Wire
Definium Therapeutics Announces New Employee Inducement Grants - Business Wire
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 - Lelezard
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics' Upcoming Phase 3 Data on DT120 to De-Risk Program, Back FDA Approval, RBC Says - marketscreener.com
DFTX Reiterated by RBC Capital -- Price Target Maintained at $66.00 - GuruFocus
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026 - BioSpace
Definium Therapeutics (DFTX) Showcases Phase 3 Data Amid High Va - GuruFocus
DFTXDefinium Therapeutics Inc Revenue Breakdown - Finviz
Definium Therapeutics CEO Robert Barrow Sells 19,023 Shares Following 40,000-Share Award - Kalkine Media
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Secures Second FDA Breakthrough Therapy Designation for DT120 in MDD - Minichart
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
Definium Therapeutics Inc (DFTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.06%
2.55%
자본화:
|
볼륨(24시간):